PIK3CA and aneurysmal bone cyst: A similar safety profile of alpelisib was observed in the Phase II 3-cohort BYLieve study, which assesses the safety and efficacy of alpelisib with ET (fulvestrant/letrozole) in patients with HR+, HER2–, PIK3CA-mutated ABC whose disease progressed on/after prior treatments17,20–23.